News &
Publications

Contacts

Franklin Hoke
Vice President
for Communications
215-728-2700
215-475-2888 (cell phone)
Franklin.Hoke@fccc.edu

Diana Quattrone
Director of Media Relations
215-728-7784
215-815-7828 (cell phone)
Diana.Quattrone@fccc.edu

Communications Staff

 

News

Fox Chase Cancer Center Exceeds Campaign Goal for the Prevention Pavilion

PHILADELPHIA (April 12, 2000) -- With more than a year remaining in the campaign to raise $38 million for the Research Institute for Cancer Prevention, Fox Chase Cancer Center president Robert C. Young, M.D. announced today the goal has been achieved.

"We are most grateful for the generous gifts we received from individuals, corporations, and foundations including a $250,000 gift and two $25,000 gifts received just this morning," said Young. Today's gifts meant the completion of the campaign a year and two months before it was scheduled to end.

"Our Board of Directors set the pace early with generous gifts. Their unprecedented giving and 100 percent participation demonstrates their commitment to Fox Chase and the prevention of cancer.

"Other companies and nonprofit foundations from around the country and abroad have been very generous in their support. The reputation and worldwide prestige of these important corporations provided scientific and corporate endorsement of our ideas for prevention," added Young.

Early leadership gifts included $11.5 million from five foundations: The Connelly Foundation of West Conshohocken, Pa., The Dyson Foundation of Millerton, N.Y., The Kresge Foundation of Troy, Mich., The Pew Charitable Trusts of Philadelphia and The W. W. Smith Charitable Trust of Newtown Square, Pa.

A total of $5.15 million has come from 12 corporate donors:

  • Berlex Laboratories, based in New Jersey and Richmond, Calif.;
  • BetzDearborn Inc., formerly of Trevose, Pa., now a chemical subsidiary of Hercules Inc. of Wilmington, Del.;
  • Bristol-Myers Squibb Company, whose oncology division is based in Princeton, NJ;
  • Crown Cork & Seal Co. of Philadelphia;
  • Eli Lilly and Company, Indianapolis, Indiana;
  • Novartis Pharmaceuticals Corporation, located in East Hanover, NJ;
  • Ortho Biotech Inc. and Janssen Pharmaceutica, New Jersey-based members of the Johnson & Johnson family of companies;
  • Rhne-Poulenc Rorer, a Collegeville, Pa.-based subsidiary of Rhne-Poulenc S.A. of Paris, France;
  • Rohm and Haas Company of Philadelphia;
  • Penn Mutual Life Insurance Company of Horsham, Pa.;
  • SmithKline Beecham of Philadelphia and London, England.

Much of this support helped fund construction of the Prevention Pavilion that houses the new Fox Chase research initiative. The building and laboratory equipment represent $22.6 million of the total $38 million campaign while the remaining money has been allocated to endowed faculty chairs and postdoctoral fellowships and new research programs.

Fox Chase raised more than $5.4 million in new gifts and grants by September 1999 in order to meet the Kresge Foundation's 1998 challenge grant of $1.5 million. The grant is one of the largest challenge grants Kresge made in 1998 and the largest ever made to a Pennsylvania institution.

The five-level, 120,000-square-foot Prevention Pavilion is now complete. Scientists are beginning to set up their lab space inside the new building. The ceremonial opening for the Prevention Pavilion will take place this evening, April 12, 2000.

Scientific investigations to be pursued in the Research Institute for Cancer Prevention include programs in genetics; genetic epidemiology--the study of disease patterns on a molecular level; risk assessment; behavioral medicine; chemoprevention--the use of medication to prevent cancer; and bioinformatics.

In addition to research laboratories, the Prevention Pavilion will house clinical programs for people at high risk of cancer, including genetically driven cancer screening and counseling.

Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at: www.fccc.edu.


Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach.  For more information, call 1-888-FOX CHASE or (1-888-369-2427).

More 2000 News Releases »